Evaluating Success of Therapy for Bronchiectasis. What End Points to Use?

Clinics in Chest Medicine

Volumn 33, Issue 2, 2012, Pages 329-349

  Smith, Maeve P ^a   Hill, Adam T ^a,b  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Bronchiectasis; End points; Treatment

Indexed keywords

AMOXICILLIN; BECLOMETASONE; BUDESONIDE; C REACTIVE PROTEIN; CEFTAZIDIME; DORNASE ALFA; ERYTHROMYCIN; FLUTICASONE; FORMOTEROL; GENTAMICIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 8; LEUKOCYTE ELASTASE; LEUKOTRIENE B4; MANNITOL; MYELOPEROXIDASE; PLACEBO; PROCALCITONIN; SODIUM CHLORIDE; TOBRAMYCIN; TUMOR NECROSIS FACTOR ALPHA;

BRONCHIECTASIS; CLINICAL EFFECTIVENESS; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG MEGADOSE; ERYTHROCYTE SEDIMENTATION RATE; EXERCISE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INTERVENTION STUDY; LEUKOCYTE COUNT; LONG TERM CARE; LUNG CLEARANCE; OUTCOME ASSESSMENT; PHYSIOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE INDEX; REVIEW; SPIROMETRY; SPUTUM EXAMINATION; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; BRONCHIECTASIS; EXERCISE TOLERANCE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY FUNCTION TESTS; SPUTUM; TREATMENT OUTCOME;

EID: 84861542516     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2012.03.001     Document Type: Review

References (70)

1. Grainger-Stewart T. On the treatment of bronchiectasis. Br Med J 1893, 1:1147-1148.
2. Athanazio R.A., Rached S.Z., Rohde C., et al. Should the bronchiectasis treatment given to cystic fibrosis patients be extrapolated to those with bronchiectasis from other causes?. J Bras Pneumol 2010, 36(4):425-431.
3. Loebinger M.R., Wells A.U., Hansell D.M., et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009, 34(4):843-849.
4. Finklea J.D., Khan G., Thomas S., et al. Predictors of mortality in hospitalized patients with acute exacerbation of bronchiectasis. Respir Med 2010, 104(6):816-821.
5. Roberts H.J., Hubbard R. Trends in bronchiectasis mortality in England and Wales. Respir Med 2010, 104(7):981-985.
6. Thompson C.S., Harrison S., Ashley J., et al. Randomised crossover study of the Flutter device and the active cycle of breathing technique in non-cystic fibrosis bronchiectasis. Thorax 2002, 57(5):446-448.
7. Elborn J.S., Johnston B., Allen F., et al. Inhaled steroids in patients with bronchiectasis. Respir Med 1992, 86(2):121-124.
8. Kellett F., Robert N.M. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med 2011, 105(12):1831-1835.
9. O'Donnell A.E., Barker A.F., Ilowite J.S., et al. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998, 113(5):1329-1334.
10. King P.T., Holdsworth S.R., Freezer N.J., et al. Lung diffusing capacity in adult bronchiectasis: a longitudinal study. Respir Care 2010, 55(12):1686-1692.
11. Moran F., Piper A., Elborn J.S., et al. Respiratory muscle pressures in non-CF bronchiectasis: repeatability and reliability. Chron Respir Dis 2010, 7(3):165-171.
12. Liaw M.Y., Wang Y.H., Tsai Y.C., et al. Inspiratory muscle training in bronchiectasis patients: a prospective randomized controlled study. Clin Rehabil 2011, 25(6):524-536.
13. Robinson P.D., Goldman M.D., Gustafsson P.M. Inert gas washout: theoretical background and clinical utility in respiratory disease. Respiration 2009, 78(3):339-355.
14. Horsley A.R., Gustafsson P.M., Macleod K.A., et al. Lung clearance index is a sensitive, repeatable and practical measure of airways disease in adults with cystic fibrosis. Thorax 2008, 63(2):135-140.
15. Gustafsson P.M. Peripheral airway involvement in CF and asthma compared by inert gas washout. Pediatr Pulmonol 2007, 42(2):168-176.
16. Pasteur M.C., Helliwell S.M., Houghton S.J., et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000, 162(4 Pt 1):1277-1284.
17. Angrill J., Agusti C., de Celis R., et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002, 57(1):15-19.
18. King P.T., Holdsworth S.R., Freezer N.J., et al. Microbiologic follow-up study in adult bronchiectasis. Respir Med 2007, 101(8):1633-1638.
19. Angrill J., Agusti C., De Celis R., et al. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med 2001, 164(9):1628-1632.
20. Hill A.T., Campbell E.J., Hill S.L., et al. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000, 109(4):288-295.
21. Wilson C.B., Jones P.W., O'Leary C.J., et al. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 1997, 10(8):1754-1760.
22. Ho P.L., Chan K.N., Ip M.S., et al. The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis. Chest 1998, 114(6):1594-1598.
23. Davies G., Wells A.U., Doffman S., et al. The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. Eur Respir J 2006, 28(5):974-979.
24. Stockley R.A., Bayley D., Hill S.L., et al. Assessment of airway neutrophils by sputum colour: correlation with airways inflammation. Thorax 2001, 56(5):366-372.
25. Murray M.P., Pentland J.L., Turnbull K., et al. Sputum colour: a useful clinical tool in non-cystic fibrosis bronchiectasis. Eur Respir J 2009, 34(2):361-364.
26. Prolonged antibiotic treatment of severe bronchiectasis; a report by a subcommittee of the Antibiotics Clinical Trials (non-tuberculous) Committee of the Medical Research Council. Br Med J 1957, 2(5039):255-259.
27. Currie D.C., Garbett N.D., Chan K.L., et al. Double-blind randomized study of prolonged higher-dose oral amoxycillin in purulent bronchiectasis. Q J Med 1990, 76(280):799-816.
28. Scheinberg P., Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005, 127(4):1420-1426.
29. Murray M.P., Govan J.R., Doherty C.J., et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011, 183(4):491-499.
30. Tsang K.W., Tan K.C., Ho P.L., et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax 2005, 60(3):239-243.
31. Murray M.P., Pentland J.L., Hill A.T. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J 2009, 34(5):1086-1092.
32. Stockley R.A., Hill S.L., Morrison H.M., et al. Elastolytic activity of sputum and its relation to purulence and to lung function in patients with bronchiectasis. Thorax 1984, 39(6):408-413.
33. Currie D.C., Saverymuttu S.H., Peters A.M., et al. Indium-111-labelled granulocyte accumulation in respiratory tract of patients with bronchiectasis. Lancet 1987, 1(8546):1335-1339.
34. Gaga M., Bentley A.M., Humbert M., et al. Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis. Thorax 1998, 53(8):685-691.
35. Stockley R.A., Hill S.L., Morrison H.M. Effect of antibiotic treatment on sputum elastase in bronchiectatic outpatients in a stable clinical state. Thorax 1984, 39(6):414-419.
36. Tsang K.W., Ho P.I., Chan K.N., et al. A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 1999, 13(2):361-364.
37. Tsang K.W., Ho P.L., Lam W.K., et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med 1998, 158(3):723-727.
38. Loukides S., Bouros D., Papatheodorou G., et al. Exhaled H(2)O(2) in steady-state bronchiectasis: relationship with cellular composition in induced sputum, spirometry, and extent and severity of disease. Chest 2002, 121(1):81-87.
39. Loukides S., Horvath I., Wodehouse T., et al. Elevated levels of expired breath hydrogen peroxide in bronchiectasis. Am J Respir Crit Care Med 1998, 158(3):991-994.
40. Shoemark A., Devaraj A., Meister M., et al. Elevated peripheral airway nitric oxide in bronchiectasis reflects disease severity. Respir Med 2011, 105(6):885-891.
41. Loebinger M.R., Shoemark A., Berry M., et al. Procalcitonin in stable and unstable patients with bronchiectasis. Chron Respir Dis 2008, 5(3):155-160.
42. Murray M.P., Turnbull K., Macquarrie S., et al. Assessing response to treatment of exacerbations of bronchiectasis in adults. Eur Respir J 2009, 33(2):312-318.
43. Wilson C.B., Jones P.W., O'Leary C.J., et al. Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 1997, 156(2 Pt 1):536-541.
44. Murray M.P., Turnbull K., MacQuarrie S., et al. Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Eur Respir J 2009, 34(1):125-131.
45. Jones P.W., Quirk F.H., Baveystock C.M., et al. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992, 145(6):1321-1327.
46. Birring S.S., Prudon B., Carr A.J., et al. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax 2003, 58(4):339-343.
47. Guyatt G.H., Berman L.B., Townsend M., et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987, 42(10):773-778.
48. Quittner A.L., Salathe M., Gotfried M., et al. National validation of a patient-reported outcome measure for bronchiectasis: psychometric results on the QOL-B. Am J Respir Crit Care Med 2010, 181:A5793.
49. Quittner A.L., Marciel K., Kimberg C., et al. Content validity of a disease-specific patient reported outcome for bronchiectasis. Chest 2011, 140:453A.
50. Singh S.J., Morgan M.D., Scott S., et al. Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax 1992, 47(12):1019-1024.
51. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166(1):111-117.
52. Lee A.L., Button B.M., Ellis S., et al. Clinical determinants of the 6-Minute Walk Test in bronchiectasis. Respir Med 2009, 103(5):780-785.
53. Martinez-Garcia M.A., Soler-Cataluna J.J., Perpina-Tordera M., et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007, 132(5):1565-1572.
54. Martinez-Garcia M.A., Perpina-Tordera M., Roman-Sanchez P., et al. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest 2005, 128(2):739-745.
55. Courtney J.M., Kelly M.G., Watt A., et al. Quality of life and inflammation in exacerbations of bronchiectasis. Chron Respir Dis 2008, 5(3):161-168.
56. Pasteur M.C., Bilton D., Hill A.T. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010, 65(Suppl 1):i1-58.
57. Orriols R., Roig J., Ferrer J., et al. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir Med 1999, 93(7):476-480.
58. Barker A.F., Couch L., Fiel S.B., et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000, 162(2 Pt 1):481-485.
59. Patterson J.E., Bradley J.M., Elborn J.S. Airway clearance in bronchiectasis: a randomized crossover trial of active cycle of breathing techniques (incorporating postural drainage and vibration) versus test of incremental respiratory endurance. Chron Respir Dis 2004, 1(3):127-130.
60. Martinez-Garcia M.A., Perpina-Tordera M., Roman-Sanchez P., et al. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Respir Med 2006, 100(9):1623-1632.
61. Martinez-Garcia M.A., Soler-Cataluna J.J., Catalan-Serra P., et al. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest 2012, 141(2):461-468.
62. Daviskas E., Anderson S.D., Gomes K., et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology 2005, 10(1):46-56.
63. Couch L.A. Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa. Chest 2001, 120(Suppl 3):114S-117S.
64. Eaton T., Young P., Zeng I., et al. A randomized evaluation of the acute efficacy, acceptability and tolerability of flutter and active cycle of breathing with and without postural drainage in non-cystic fibrosis bronchiectasis. Chron Respir Dis 2007, 4(1):23-30.
65. Newall C., Stockley R.A., Hill S.L. Exercise training and inspiratory muscle training in patients with bronchiectasis. Thorax 2005, 60(11):943-948.
66. Mutalithas K., Watkin G., Willig B., et al. Improvement in health status following bronchopulmonary hygiene physical therapy in patients with bronchiectasis. Respir Med 2008, 102(8):1140-1144.
67. Ong H.K., Lee A.L., Hill C.J., et al. Effects of pulmonary rehabilitation in bronchiectasis: a retrospective study. Chron Respir Dis 2011, 8(1):21-30.
68. Drobnic M.E., Sune P., Montoro J.B., et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005, 39(1):39-44.
69. Davies G., Wilson R. Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax 2004, 59(6):540-541.
70. Serisier D.J., Martin M.L. Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respir Med 2011, 105(6):946-949.